S-1/A: Kiromic Biopharma Eyes NYSE American Listing with Proposed Unit Offering

Kiromic Biopharma is seeking to raise capital through a unit offering to fund clinical development and working capital, contingent on listing its stock and warrants on the NYSE American.

Summary

• Kiromic Biopharma is offering up to 1,000,000 units, each consisting of one share of common stock and one warrant to purchase one share of common stock, with an assumed public offering price of $15.00 per unit.
• The company intends to use the net proceeds for pre-clinical and clinical development, working capital, and other general corporate purposes.
• Kiromic's lead product candidate, Deltacel, is currently in a Phase 1 clinical trial evaluating its effectiveness in combination with low-dose targeted radiation for patients with stage 4 or locally-advanced non-small cell lung cancer (NSCLC).
• The company has registered a 6-month median Progression Free Survival (PFS) with a median length of follow-up of over 10 months and the longest PFS of 12 months in the Deltacel-01 study.
• Kiromic is also developing Isocel and Procel, which are in the preclinical development stage.
• The company intends to apply to list its common stock and warrants on the NYSE American under the symbols KRBP and KRBPW, respectively, which is a condition to this offering.
• Kiromic estimates net proceeds from the offering to be $13.5 million, or $15.6 million if the underwriters exercise their over-allotment option in full.
• The company effected a 1-for-10 reverse stock split prior to the effective date of the registration statement.

Sentiment

Score: 5

Explanation: The document presents a mixed sentiment. While there are positive aspects such as the Fast Track Designation for Deltacel and promising early clinical results, the company's financial situation and the risks associated with drug development temper the overall outlook.

Positives

• Deltacel has received Fast Track Designation from the FDA, potentially accelerating its approval process.
• The company has registered a 6-month median Progression Free Survival (PFS) with a median length of follow-up of over 10 months and the longest PFS of 12 months in the Deltacel-01 study.
• The company is developing novel, virus-free cell engineering methods.
• The company has an Artificial Intelligence platform for the identification and prioritization of the next generation of biomarkers.

Negatives

• Kiromic has incurred losses since inception and may never achieve or sustain profitability.
• The company will need substantial additional funding and cannot be certain that additional capital will be available.
• The company's financial situation creates doubt about its ability to continue as a going concern.
• The company has never commercialized a product.
• The company is dependent on third parties for the supply of various biological materials.

Risks

• The company's tumor-specific cancer immunotherapy approach exposes it to unforeseen risks.
• Delays in patient enrollment for clinical trials could significantly delay or prevent regulatory approvals.
• The FDA regulatory approval process is lengthy and time-consuming, and the company may experience significant delays.
• The company may be subject to securities laws claims regarding past disclosures.
• The company is increasingly dependent on its information technology systems and infrastructure for its business.

Future Outlook

The company plans to continue the development of Isocel and Procel once it gathers sufficient financial support and expects to be able to submit the Isocel IND in the second half of 2025, and the Procel IND in the second quarter of 2026.

Industry Context

The company operates in the competitive biopharmaceutical industry, focusing on solid tumor therapies, which represent a significant portion of the oncology market. The company faces competition from other companies developing allogeneic T cell therapies and other immunotherapies.

Comparison to Industry Standards

• The document mentions competitors such as Fate Therapeutics, Poseida Therapeutics, Allogene Therapeutics, Adicet Bio, Inc., Cytomed Therapeutics, IN8 Bio, Inc. TC Biopharm Limited, GammaDelta Therapeutics Limited (acquired by Takeda) in the allogeneic cell therapy space.
• The document also mentions competition from large-cap pharmaceutical companies such as Amgen Inc., AstraZeneca plc, Bristol-Myers Squibb Company, Incyte Corporation, Merck & Co., Inc., and F. Hoffmann-La Roche AG, which are pursuing non-cell-based immune and other biologics.

Legal Proceedings

• The company finalized a settlement with the SEC on December 3, 2024, resolving an investigation related to non-disclosure of clinical holds.
• The company was involved in a class action lawsuit, which was settled in principle on August 7, 2023.

Stakeholder Impact

• Shareholders may experience dilution due to the unit offering.
• Employees' job security is uncertain due to the company's financial situation.
• Patients may benefit from the development of new cancer therapies.
• Suppliers and creditors face increased risk due to the company's financial instability.

Next Steps

• Complete Phase 1 trial enrollment for Deltacel-01 by March 2025.
• Seek feedback from the FDA regarding the design of the pivotal Phase 2 trial for Deltacel between June and August 2025.
• Potentially submit a BTD application in Q4 2025.
• Submit the IND for the Deltacel pivotal phase 2 trial and the IND for Isocel in H2 2025 (subject to financing).
• Submit the IND for Procel in 2026 (subject to financing).

Key Dates

Keywords

Kiromic Biopharma, Deltacel, Isocel, Procel, Unit Offering, NYSE American, Gamma Delta T-cell therapy, Clinical Trials, FDA, BioPharma